Gilead Sciences Inc. shares rose in the extended session Wednesday after the biotech drug maker topped Wall Street estimates for the quarter. Gilead shares rose 2.6% to $76.10 after hours. The company reported second-quarter net income of $3.37 billion, or $2.33 a share, compared to $4.18 billion, or $2.58 a share, in the year-ago period. Second-quarter adjusted earnings were $2.56 a share. Revenue fell to $7.14 billion from $7.78 billion in the year ago period. Analysts surveyed by FactSet had estimated adjusted earnings of $2.29 a share on revenue of $6.33 billion. For the full year, Gilead estimates revenue of $24 billion to $25.5 billion. Analysts had forecast revenue of $24.65 billion.
Copyright © 2017 MarketWatch, Inc.
Continue Reading Below